Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | PLK1 | P53350 | 7/20 | 0.53 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL250247 | 0.83 | HDAC6 (0.80) | HDAC2HDAC8HDAC6HPGDTSHR | |
| SCHEMBL8306146 | 0.82 | HDAC2 (0.64) | HDAC2HDAC8HDAC6HPGDTSHR | |
| SCHEMBL6469729 | 0.82 | MPO (0.64) | HTTCA2NPC1RAB9AMEN1 | |
| SCHEMBL18019596 | 0.80 | NPC1 (0.69) | HDAC2HDAC8HDAC6HPGDTSHR | |
| Hydrochloric Acid SCHEMBL28169553 | 0.80 | MPO (0.61) | HTTCA2MEN1LMNAPOLB | |
| SCHEMBL9787399 | 0.80 | HDAC6 (0.56) | HDAC2HDAC8HDAC6CA2 | |
| SCHEMBL15798566 | 0.79 | HDAC2 (0.55) | HDAC2HDAC8HDAC6HPGDTSHR | |
| SCHEMBL15896350 | 0.78 | HDAC2 (0.59) | HDAC2HDAC8HDAC6HPGDTSHR | |
| SCHEMBL1105657 | 0.77 | ALDH1A1 (0.60) | HDAC2HDAC8HDAC6SMN1; SMN2CA2 | |
| SCHEMBL1003914 | 0.77 | HDAC2 (0.64) | HDAC2HDAC8HDAC6HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230194537-A1 | COMPOUNDS FOR THE DETECTION OF GLYCANS | Life Technologies Corporation | 2023-06-22 | — | — | US | disclosed |
| US-8153100-B2 | Methods and compositions for F-18 labeling of proteins, peptides and other molecules | IMMUNOMEDICS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8147800-B2 | Methods and compositions for F-18 labeling of proteins, peptides and other molecules | IMMUNOMEDICS, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110280801-A1 | Methods and Compositions for F-18 Labeling of Proteins, Peptides and Other Molecules | IMMUNOMEDICS, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20090246130-A1 | Methods and Compositions for F-18 Labeling of Proteins, Peptides and Other Molecules | IMMUNOMEDICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090246130-A1 | Methods and Compositions for F-18 Labeling of Proteins, Peptides and Other Molecules | F13B, TFRC, F13A1 | HDAC2 4534/4885HDAC8 3885/4885HDAC6 2982/4885 |
| US-20110280801-A1 | Methods and Compositions for F-18 Labeling of Proteins, Peptides and Other Molecules | TFRC, F13A1, S100A8 | HDAC2 4562/4885HDAC8 2423/4885HDAC6 3032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.